Iparomlimab and Tuvonralimab plus radiation and chemo for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) with low-dose radiation and chemotherapy for advanced head and neck cancer. It aims to see if this approach can help patients who have not had prior treatment for their cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced head and neck squamous cell cancer (stage III to IVB) that has not been treated before.
- You are in fairly good health (able to do daily activities without major help).
- You have at least one tumor that can be measured on scans.
- You have adequate blood counts and liver/kidney function.
- You are not pregnant, and will use effective birth control during and after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding a checkpoint immunotherapy (tislelizumab) and a cancer pill (pamiparib) to radiation can better treat cancer that has come back in the head and neck. It’s for adults with previously treated, HPV-positive oropharynx tumors, usually without widespread spread.
This trial tests two new immunotherapy drugs, iparomlimab and tuvonralimab, for people with head and neck squamous cell cancer that has spread or come back after at least 2 prior treatments. The goal is to see if this combination can shrink or slow the cancer.
This trial tests a new combination of immunotherapy drugs plus radiation and chemotherapy for people with large, hard-to-treat head and neck cancer that hasn't spread far. It aims to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) along with standard chemotherapy and radiation for people with newly diagnosed, stage IVA nasopharyngeal cancer that has spread to lymph nodes but not to distant organs. The goal is to see if this approach can improve outcomes.
This trial tests a new combination of two immunotherapy drugs (called iparomlimab and tuvonralimab), with or without chemotherapy, for head and neck squamous cell carcinoma that has returned or spread after previous treatment. The goal is to see if this combination can help people with this cancer live longer with fewer side effects.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiation can help people with cervical cancer that has returned or spread to a few new places. The goal is to see if this combination improves outcomes for those whose cancer is no longer responding to initial treatment.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.